Elisabeth A. Lasater

Author

Also Known As

E A Lasater, E. A. Lasater, E. Lasater, Elisabeth A Lasater, Elisabeth A. Lasater, Elisabeth Lasater, Lasater, Elisabeth A.

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

University of California, San Francisco University of Pennsylvania UCSF Helen Diller Family Comprehensive Cancer Center Jewish General Hospital Rutgers, The State University of New Jersey

About

Elisabeth A. Lasater is an author at University of California, San Francisco specializing in medicine, cancer research, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	638
2	Cell Biology	3	3	267
3	Immunology	3	3	233
4	Pharmacology	2	2	405
5	Pathology	1	1	24

Elisabeth A. Lasater

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia Christine M. McMahon, Timothy T. Ferng, Jonathan Canaani, Cancer Discovery	2019	412
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology Pietro Ciceri, Susanne Müller, Alison O’Mahony, Nature Chemical Biology Molecular PharmacologyMedicinal ChemistryMedicineDual Kinase-bromodomain InhibitorsRational Drug Design	2014	347
Crenolanib is a selective type I pan-FLT3 inhibitor Catherine C. Smith, Elisabeth A. Lasater, Kimberly C. Lin, Proceedings of the National Academy of Sciences	2014	207
Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 “Gatekeeper” F691L Mutation with PLX3397 Catherine C. Smith, Chao Zhang, Kimberly C. Lin, Cancer Discovery	2015	197
Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models Raghuveer Singh Mali, Qi Zhang, RosaAnna DeFilippis, Haematologica Venetoclax MonotherapyHematological MalignancyVenetoclax CombinesLeukemic CellsMedicine	2020	134
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD Catherine C. Smith, Elisabeth A. Lasater, Xiaotian Zhu, Blood	2013	127
Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint Blockade Frederick J. Kohlhapp, Dipica Haribhai, Rebecca Mathew, Cancer Discovery	2020	124
Genetic and cellular evidence of vascular inflammation in neurofibromin-deficient mice and humans Elisabeth A. Lasater, Fang Li, Waylan Bessler, Journal of Clinical Investigation	2010	79
The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia Katherine A. Minson, Catherine C. Smith, Deborah DeRyckere, JCI Insight Fms-like Tyrosine KinaseMixed-phenotype Acute LeukemiaResistance-conferring Flt3 MutationsImmunologyTumor Biology	2016	75
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma Marta Larráyoz, María J. García‐Barchino, Jon Celay, Nature Medicine	2023	75

Page 1